Damage-associated molecular patterns and their pathological relevance in diabetes mellitus

Ageing Research Reviews

Volumn 24, Issue , 2015, Pages 66-76

  Shin, Jung Jae ^a   Lee, Eun Kyung ^b   Park, Tae Joo ^c   Kim, Wook ^a  

^a Ajou University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Ulsan National Institute of Science and Technology   (South Korea)

Author keywords

Damage associated molecular pattern (DAMP); Diabetes; Inflammasome; Inflammation; Pattern recognition receptor (PRR)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLIN; CERAMIDE; GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; PALMITIC ACID; PATTERN RECOGNITION RECEPTOR; PROTEIN S 100;

ADAPTIVE IMMUNITY; APOPTOSIS; CELL DEATH; CELL INFILTRATION; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DAMAGE ASSOCIATED MOLECULAR PATTERN; GLUCOSE TOLERANCE; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MACROPHAGE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; AGING; ANIMAL; DIABETES MELLITUS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

AGING; ANIMALS; DIABETES MELLITUS; HUMANS; INFLAMMASOMES; RECEPTORS, PATTERN RECOGNITION;

EID: 84947045864     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2015.06.004     Document Type: Review

References (105)

1. Addy C., Wright H., Van Laere K., Gantz I., Erondu N., Musser B.J., Lu K., Yuan J., Sanabria-Bohórquez S.M., Stoch A., Stevens C., Fong T.M., De Lepeleire I., Cilissen C., Cote J., Rosko K., Gendrano I.N., Nguyen A.M., Gumbiner B., Rothenberg P., de Hoon J., Bormans G., Depré M., Eng W.S., Ravussin E., Klein S., Blundell J., Herman G.A., Burns H.D., Hargreaves R.J., Wagner J., Gottesdiener K., Amatruda J.M., Heymsfield S.B. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008, 7:68-78.
2. Ahlgren U., Jonsson J., Jonsson L., Simu K., Edlund H. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 1998, 12:1763-1768.
3. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2014, 37:S81-S90.
4. Ashcroft F.M. ATP-sensitive potassium channelopathies: focus on insulin secretion. J. Clin. Invest. 2005, 115:2047-2058.
5. Bailey C.J. Drugs on the horizon for diabesity. Curr. Diabetes Rep. 2005, 5:353-359.
6. Boden G. Interaction between free fatty acids and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care 2002, 5:545-549.
7. Böni-Schnetzler M., Boller S., Debray S., Bouzakri K., Meier D.T., Prazak R., Kerr-Conte J., Pattou F., Ehses J.A., Schuit F.C., Donath M.Y. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009, 150:5218-5229.
8. Böni-Schnetzler M., Thorne J., Parnaud G., Marselli L., Ehses J.A., Kerr-Conte J., Pattou F., Halban P.A., Weir G.C., Donath M.Y. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 2008, 93:4065-4074.
9. Calogero S., Grassi F., Aguzzi A., Voigtländer T., Ferrier P., Ferrari S., Bianchi M.E. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 1999, 22:276-280.
10. Cavelti-Weder C., Babians-Brunner A., Keller C., Stahel M.A., Kurz-Levin M., Zayed H., Solinger A.M., Mandrup-Poulsen T., Dinarello C.A., Donath M.Y. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012, 35:1654-1662.
11. Chavez J.A., Knotts T.A., Wang L.P., Li G., Dobrowsky R.T., Florant G.L., Summers S.A. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J. Biol. Chem. 2003, 278:10297-10303.
12. Chen G.Y., Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
13. Chen Y., Yan S.S., Colgan J., Zhang H.P., Luban J., Schmidt A.M., Stern D., Herold K.C. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J. Immunol. 2004, 173:1399-1405.
14. Daneman D. Type 1 diabetes. Lancet 2006, 367:847-858.
15. Dardano A., Penno G., Del Prato S., Miccoli R. Optimal therapy of type 2 diabetes: a controversial challenge. Aging (Albany NY) 2014, 6(3):187-206.
16. Després J.P., Golay A., Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 2005, 353:2121-2134. Rimonabant in Obesity-Lipids Study Group.
17. Di Marzo V., De Petrocellis L., Sepe N., Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 1996, 316:977-984.
18. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
19. Donath M.Y. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat. Rev. Drug Discovery 2014, 13:465-476.
20. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
21. Donath M.Y., Størling J., Maedler K., Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med. (Berl.) 2003, 81:455-470.
22. Ehses J.A., Meier D.T., Wueest S., Rytka J., Boller S., Wielinga P.Y., Schraenen A., Lemaire K., Debray S., Van Lommel L., Pospisilik J.A., Tschopp O., Schultze S.M., Malipiero U., Esterbauer H., Ellingsgaard H., Rütti S., Schuit F.C., Lutz T.A., Böni-Schnetzler M., Konrad D., Donath M.Y. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 2010, 53:1795-1806.
23. Ehses J.A., Lacraz G., Giroix M.H., Schmidlin F., Coulaud J., Kassis N., Irminger J.C., Kergoat M., Portha B., Homo-Delarche F., Donath M.Y. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13998-14003.
24. Grant R.W., Dixit V.D. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front. Immunol. 2013, 4:50.
25. Grishman E.K., White P.C., Savani R.C. Toll-like receptors, the NLRP3 inflammasome, and interleukin-1β in the development and progression of type 1 diabetes. Pediatr. Res. 2012, 71:626-632.
26. Han K.H., Lim S., Ryu J., Lee C.W., Kim Y., Kang J.H., Kang S.S., Ahn Y.K., Park C.S., Kim J.J. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc. Res. 2009, 84:378-386.
27. Hensen J., Howard C.P., Walter V., Thuren T. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 2013, 39:524-531.
28. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., Schmidt A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901.
29. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., Morser J., Stern D., Schmidt A.M. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995, 270:25752-25761.
30. Huang J., Xie Y., Sun X., Zeh H.J., Kang R., Lotze M.T., Tang D. DAMPs, ageing, and cancer: the 'DAMP Hypothesis'. Ageing Res. Rev. 2014, 10.1016/j.arr.2014.10.004.
31. Jourdan T., Djaouti L., Demizieux L., Gresti J., Vergès B., Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010, 59:926-934.
32. Jourdan T., Godlewski G., Cinar R., Bertola A., Szanda G., Liu J., Tam J., Han T., Mukhopadhyay B., Skarulis M.C., Ju C., Aouadi M., Czech M.P., Kunos G. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat. Med. 2013, 19:1132-1140.
33. Kasuga M. Insulin resistance and pancreatic beta cell failure. J. Clin. Invest. 2006, 116:1756-1760.
34. Kim W., Doyle M.E., Liu Z., Lao Q., Shin Y.K., Carlson O.D., Kim H.S., Thomas S., Napora J.K., Lee E.K., Moaddel R., Wang Y., Maudsley S., Martin B., Kulkarni R.N., Egan J.M. Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells. Diabetes 2011, 60:1198-1209.
35. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 2008, 60(Dec (4)):470-512.
36. Kim W., Lao Q., Shin Y.K., Carlson O.D., Lee E.K., Gorospe M., Kulkarni R.N., Egan J.M. Cannabinoids induce pancreatic β-cell death by directly inhibiting insulin receptor activation. Sci. Signal. 2012, 5:ra23.
37. Kitamura T., Nakae J., Kitamura Y., Kido Y., Biggs W.H., Wright C.V., White M.F., Arden K.C., Accili D. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J. Clin. Invest. 2002, 110:1839-1847.
38. Koenen T.B., Stienstra R., van Tits L.J., de Graaf J., Stalenhoef A.F., Joosten L.A., Tack C.J., Netea M.G. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue. Diabetes 2011, 60:517-524.
39. Kono H., Rock K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008, 8:279-289.
40. Lamkanfi M., Mueller J.L., Vitari A.C., Misaghi S., Fedorova A., Deshayes K., Lee W.P., Hoffman H.M., Dixit V.M. Glyburide inhibits the cryopyrin/Nalp3 inflammasome. J. Cell Biol. 2009, 187:61-70.
41. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M.Y., Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32:1663-1668.
42. Larsen C.M., Faulenbach M., Vaag A., Vølund A., Ehses J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
43. Lee B.W., Chae H.Y., Kwon S.J., Park S.Y., Ihm J., Ihm S.H. RAGE ligands induce apoptotic cell death of pancreatic β-cells via oxidative stress. Int. J. Mol. Med. 2010, 26:813-818.
44. Lee H.M., Kim J.J., Kim H.J., Shong M., Ku B.J., Jo E.K. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013, 62:194-204.
45. Le Foll B., Gorelick D.A., Goldberg S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009, 205:171-174.
46. LoVerme J., Duranti A., Tontini A., Spadoni G., Mor M., Rivara S., Stella N., Xu C., Tarzia G., Piomelli D. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg. Med. Chem. Lett. 2009, 19:639-643.
47. Lukens J.R., Gross J.M., Kanneganti T.D. IL-1 family cytokines trigger sterile inflammatory disease. Front. Immunol. 2012, 3:315.
48. Maedler K., Dharmadhikari G., Schumann D.M., Størling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin. Biol. Ther. 2009, 9:1177-1188.
49. Maedler K., Sergeev P., Ris F., Oberholzer J., Joller-Jemelka H.I., Spinas G.A., Kaiser N., Halban P.A., Donath M.Y. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002, 110:851-860.
50. Maedler K., Schumann D.M., Sauter N., Ellingsgaard H., Bosco D., Baertschiger R., Iwakura Y., Oberholzer J., Wollheim C.B., Gauthier B.R., Donath M.Y. Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes 2006, 55:2713-2722.
51. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996, 39:1005-1029.
52. Mandrup-Poulsen T., Pickersgill L., Donath M.Y. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2010, 6:158-166.
53. Masson E., Koren S., Razik F., Goldberg H., Kwan E.P., Sheu L., Gaisano H.Y., Fantus I.G. High beta-cell mass prevents streptozotocin-induced diabetes in thioredoxin-interacting protein-deficient mice. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E1251-E1261.
54. Masters S.L., Dunne A., Subramanian S.L., Hull R.L., Tannahill G.M., Sharp F.A., Becker C., Franchi L., Yoshihara E., Chen Z., Mullooly N., Mielke L.A., Harris J., Coll R.C., Mills K.H., Mok K.H., Newsholme P., Nuñez G., Yodoi J., Kahn S.E., Lavelle E.C., O'Neill L.A. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 2010, 11:897-904.
55. Mathis D., Vence L., Benoist C. β-Cell death during progression to diabetes. Nature 2001, 414:792-798.
56. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006, 91:3171-3180.
57. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
58. Mbitikon-Kobo F.M., Vocanson M., Michallet M.C., Tomkowiak M., Cottalorda A., Angelov G.S., Coupet C.A., Djebali S., Marçais A., Dubois B., Bonnefoy-Bérard N., Nicolas J.F., Arpin C., Marvel J. Characterization of a CD44/CD122int memory CD8 T cell subset generated under sterile inflammatory conditions. J. Immunol. 2009, 182:3846-3854.
59. Minn A.H., Hafele C., Shalev A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 2005, 146:2397-2405.
60. Montane J., Cadavez L., Novials A. Stress and the inflammatory process: a major cause of pancreatic cell death in type 2 diabetes. Diabetes Metab. Syndr. Obes. 2014, 7:25-34.
61. Nuki G., Bresnihan B., Bear M.B., McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46:2838-2846. European Group of Clinical Investigators.
62. Ohlsson H., Karlsson K., Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J. 1993, 12:4251-4259.
63. Pacher P., Kunos G. Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J. 2013, 280:1918-1943.
64. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284:R345-R353.
65. Rissanen A., Howard C.P., Botha J., Thuren T. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes. Metab. 2012, 14:1088-1096. Global Investigators.
66. Rock K.L., Latz E., Ontiveros F., Kono H. The sterile inflammatory response. Annu. Rev. Immunol. 2010, 28:321-342.
67. Rosenstock J., Hollander P., Chevalier S., Iranmanesh A. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008, 31:2169-2176. SERENADE Study Group.
68. Rosin D.L., Okusa M.D. Dangers within: DAMP responses to damage and cell death in kidney disease. J. Am. Soc. Nephrol. 2011, 22:416-425.
69. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
70. Sauter N.S., Schulthess F.T., Galasso R., Castellani L.W., Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 2008, 149:2208-2218.
71. Schaefer L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J. Biol. Chem. 2014, 289:35237-35245.
72. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegarty H., Hurley W., Clauss M., Wang F., Pan Y.C.E., Tsang T.C., Stern D. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 1992, 267:14987-14997.
73. Schott W.H., Haskell B.D., Tse H.M., Milton M.J., Piganelli J.D., Choisy-Rossi C.M., Reifsnyder P.C., Chervonsky A.V., Leiter E.H. Caspase-1 is not required for type 1 diabetes in the NOD mouse. Diabetes 2004, 53:99-104.
74. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
75. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
76. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 2004, 4:469-478.
77. Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B., Carpenter S.B., Becker C.E., Ediriweera H.N., Mullick A.E., Golenbock D.T., Stuart L.M., Latz E., Fitzgerald K.A., Moore K.J. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 2013, 14:812-820.
78. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006, 116:3015-3025.
79. Shu T., Zhu Y., Wang H., Lin Y., Ma Z., Han X. AGEs decrease insulin synthesis in pancreatic β-cell by repressing Pdx-1 protein expression at the post-translational level. PLoS ONE 2011, 6:e18782.
80. Sloan-Lancaster J., Abu-Raddad E., Polzer J., Miller J.W., Scherer J.C., De Gaetano A., Berg J.K., Landschulz W.H. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 2013, 36:2239-2246.
81. Son M.H., Kim H.D., Chae Y.N., Kim M.K., Shin C.Y., Ahn G.J., Choi S.H., Yang E.K., Park K.J., Chae H.W., Moon H.S., Kim S.H., Shin Y.G., Yoon S.H. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int. J. Obes. (Lond.) 2010, 34:547-556.
82. Spranger J., Kroke A., Möhlig M., Hoffmann K., Bergmann M.M., Ristow M., Boeing H., Pfeiffer A.F. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
83. Stienstra R., Joosten L.A., Koenen T., van Tits B., van Diepen J.A., van den Berg S.A., Rensen P.C., Voshol P.J., Fantuzzi G., Hijmans A., Kersten S., Müller M., van den Berg W.B., van Rooijen N., Wabitsch M., Kullberg B.J., van der Meer J.W., Kanneganti T., Tack C.J., Netea M.G. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2010, 12:593-605.
84. Stienstra R., van Diepen J.A., Tack C.J., Zaki M.H., van de Veerdonk F.L., Perera D., Neale G.A., Hooiveld G.J., Hijmans A., Vroegrijk I., van den Berg S., Romijn J., Rensen P.C., Joosten L.A., Netea M.G., Kanneganti T.D. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:15324-15329.
85. Tack C.J., Stienstra R., Joosten L.A., Netea M.G. Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol. Rev. 2012, 249:239-252.
86. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
87. Tam J., Cinar R., Liu J., Godlewski G., Wesley D., Jourdan T., Szanda G., Mukhopadhyay B., Chedester L., Liow J.S., Innis R.B., Cheng K., Rice K.C., Deschamps J.R., Chorvat R.J., McElroy J.F., Kunos G. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012, 16:167-179.
88. Tam J., Vemuri V.K., Liu J., Bátkai S., Mukhopadhyay B., Godlewski G., Osei-Hyiaman D., Ohnuma S., Ambudkar S.V., Pickel J., Makriyannis A., Kunos G. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 2010, 120:2953-2966.
89. Thomas J.O., Travers A.A. HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem. Sci. 2001, 26:167-174.
90. van Asseldonk E.J., Stienstra R., Koenen T.B., Joosten L.A., Netea M.G., Tack C.J. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2011, 96:2119-2126.
91. Vandanmagsar B., Youm Y.H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., Ravussin E., Stephens J.M., Dixit V.D. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011, 17:179-188.
92. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 1998, 12:1035-1044.
93. Wang X., Feuerstein G.Z., Gu J.L., Lysko P.G., Yue T.L. Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis 1995, 115:89-98.
94. Wang W.K., Wang B., Lu Q.H., Zhang W., Qin W.D., Liu X.J., Liu X.Q., An F.S., Zhang Y., Zhang M.X. Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int. J. Cardiol. 2014, 172:202-212.
95. Wendt T., Harja E., Bucciarelli L., Qu W., Lu Y., Rong L.L., Jenkins D.G., Stein G., Schmidt A.M., Yan S.F. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006, 185:70-77.
96. Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M.T., Brickey W.J., Ting J.P. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 2011, 12:408-415.
97. Wen H., Ting J.P., O'Neill L.A. A role for the NLRP3 inflammasome in metabolic diseases and did Warburg miss inflammation?. Nat. Immunol. 2012, 13:352-357.
98. Westermark P., Andersson A., Westermark G.T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 2011, 91:795-826.
99. Westwell-Roper C., Dai D.L., Soukhatcheva G., Potter K.J., van Rooijen N., Ehses J.A., Verchere C.B. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J. Immunol. 2011, 187:2755-2765.
100. Xie J., Méndez J.D., Méndez-Valenzuela V., Aguilar-Hernández M.M. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013, 25:2185-2197.
101. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
102. Youm Y.H., Grant R.W., McCabe L.R., Albarado D.C., Nguyen K.Y., Ravussin A., Pistell P., Newman S., Carter R., Laque A., Münzberg H., Rosen C.J., Ingram D.K., Salbaum J.M., Dixit V.D. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 2013, 18:519-532.
103. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010, 11:136-140.
104. Zhu Y., Shu T., Lin Y., Wang H., Yang J., Shi Y., Han X. Inhibition of the receptor for advanced glycation endproducts (RAGE) protects pancreatic β-cells. Biochem. Biophys. Res. Commun. 2011, 404:159-165.
105. Zóka A., Muzes G., Somogyi A., Varga T., Szémán B., Al-Aissa Z., Hadarits O., Firneisz G. Altered immune regulation in type 1 diabetes. Clin. Dev. Immunol. 2013, 2013:254874.